CHARLOTTE, N.C.--(BUSINESS WIRE)--Monarch Medical Technologies, the leader in precision insulin dosing for optimized inpatient glucose management, today announced the appointments of Carlos Mendez, MD, FACP and Brian Ulmer, MD, CDE to Monarch’s Medical Advisory Board. The board serves to advise Monarch in the continual advancement of their services and solution, the EndoTool Glucose Management System, a Class II FDA-cleared, software suite, providing personalized dosing recommendations for intravenous and subcutaneous insulin therapy.
“We are pleased to welcome Dr. Mendez and Dr. Ulmer to our Medical Advisory Board,” said Laurel Fuqua, Executive Vice President and Chief Clinical Officer of Monarch Medical Technologies. “As recognized diabetes leaders with a wealth of experience as healthcare professionals and researchers, we are confident they will be invaluable as we continue to advance our predictive insulin dosing technology and glycemic management services in the ever-evolving and expanding market of glycemic management.”
Dr. Mendez currently serves as an Associate Professor of Medicine specializing in diabetes management within the Divisions of General Internal Medicine, and Endocrinology, Diabetes, and Metabolism at the Froedtert/Medical College of Wisconsin and is the Director of the Diabetes Program at the Clement Zablocki Veterans Affairs Medical Center. Prior to this role, he was the Director of the Diabetes Management Program at the Veterans Affairs Medical Center in Albany, NY for six years. Dr. Mendez, who is originally from Venezuela, obtained his medical degree from the Universidad de Carabobo. He then proceeded to complete his residency in Internal Medicine at the John Stroger Hospital of Cook County in Chicago, IL and his Fellowship in Diabetes at the East Carolina University in Greenville, North Carolina.
Dr. Mendez has been deeply involved in academic research with multiple peer review publications and book chapters, and frequently presents lectures nationally and internationally on the management of diabetes. He is also involved in multiple organizational and leadership committees. He serves as the Associate Chair for the National Diabetes Field Advisory Committee for the Veterans Health Administration as well as the President for the American Diabetes Association Wisconsin Community Leadership Board.
“As clinical research has made clear, achieving glucose targets is associated with improved patient outcomes, shorter length of stay, and ultimately a reduction in the cost of care,” said Dr. Mendez. “Optimizing glycemic management should be a priority for hospitals, and I’m thrilled to join Monarch’s Medical Advisory Board to shed light on the importance of glycemic management within the inpatient setting and guide the company in offering a solution and services that can aid hospitals in improving the safety of their insulin dosing.”
Dr. Ulmer is a Diabetologist at St. Vincent Medical Group in Indianapolis, IN, where he serves on the Glycemic Action Committee and is the diabetes lead of the remote care monitoring program. Previously, Dr. Ulmer led an inpatient diabetes management team at Indiana University Health-Methodist Hospital in Indianapolis. He obtained a bachelor’s degree from the University of Notre Dame and completed his medical degree and residency at the Indiana University School of Medicine. Dr. Ulmer frequently lectures on inpatient glycemic management, and his clinical research interests include the safe use of insulin during hospitalization.
“Having lived with type 1 diabetes since a young age, I realize the challenges faced with inpatient insulin dosing and have dedicated my career to keeping patients safe during hospitalization,” said Dr. Ulmer. “I am honored to be involved with a company that is truly improving the standard of diabetes care while achieving excellent clinical outcomes. Monarch’s EndoTool products support physicians, nurses and hospital diabetes educators in caring for their patients while significantly lowering rates of hypoglycemia.”
To learn more about Monarch Medical Technologies, please contact firstname.lastname@example.org.
About Monarch Medical Technologies
Monarch Medical Technologies is the leading provider of electronic systems for inpatient glycemic management. Monarch’s EndoTool® Glucose Management System offers personalized dosing recommendations for intravenous and subcutaneous insulin therapy. As a Class II FDA-cleared, patent pending software suite, EndoTool has enabled more than 235 hospitals to provide unsurpassed patient-specific glycemic control across a broad population of patients, and ultimately deliver better, safer care. For more information, please visit https://monarchmedtech.com.